Abstract: The potential contributions of the mutations (N501Y, E484K, and K417N/T) contained in these variants' RBDs to the antibody pairing capability, neutralization activity, and therapeutic antibody targeting strategy are discussed.
Introduction: Figure 1 summarizes currently circulating SARS-CoV-2 variants and their respective mutations within the spike RBD, which include the following: N501Y in the UK, SA, and BR-P.1 variants; E484K/Q in the SA, BR P.1, BR P.2, NY, and IN variants; K417N/T in the SA and BR P.1 variants; L452R in the CA and IN variants; S477N in some NY variants
The emerging SARS-CoV-2 variants of concern.
PMID: 34211709
2021
Therapeutic advances in infectious disease
Discussion: D614G, like N501Y, is also suggestive of natural selection and has been seen to infect many geographic regions.
Discussion: N501Y rapidly spreads as part of the B.1.1.7 and 501.V2 clades with an affinity for
Discussion: Furthermore, a newer variant referred to as B.1.1.248 lineage has several mutations in the S protein, including N501Y and E484K.
Discussion: However, the study further showed that variants that carry K417N/T, E484K, and N501Y mutations, such as the UK (B1.1.7/501Y.V1), South African (501Y.V2), and Brazil (B1.1.28/501.V3) variants, can reduce the neutralization potency of vaccine plasma.
Insilico study on the effect of SARS-CoV-2 RBD hotspot mutants' interaction with ACE2 to understand the binding affinity and stability.
Abstract: The hotspot stabilizing residue mutations N501I, N501Y, Q493L, Q493H and K417R, strengthen the RBD-ACE2 complex by modulating the interaction statistics at the interface.
Introduction: 20 J/501Y.V3) emerged in Brazil, contains mutations K417T, E484K and N501Y in the RBD with evidence to affect transmissibility and antigenic profile.
Introduction: 20H/501Y.V2) was identified in Nelson Mandela Bay, South Africa, with multiple S protein mutations, including K417N, E484K and N501Y.|mgd
The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom.
Abstract: The N501Y, N439K, and S477N mutations caused immune escape from nine of 18 mAbs.
Result: Six of the 18 mAbs, including H00S022, 1F9, 10D12, 10F9, A247, and 11D12, displayed significantly reduced neutralizing activity against the VOC-202012/01 variant and variants carrying a single N501Y mutation ( Figure 2A ).
Result: Structure modeling of the mutation N501Y in S1 and S982A in S2 was showed asFigure 2B .
Result: The results indicated that the N439K, S477N, and N501Y mutations in the RBD could affect the susceptibility of SARS-CoV-2 variants to neutralization.
Discussion: Eight of the 17 mutations in the V
Corilagin and 1,3,6-Tri-O-galloy-beta-D-glucose: potential inhibitors of SARS-CoV-2 variants.
PMID: 34223589
2021
Physical chemistry chemical physics
Abstract: In addition to the wild-type RBD, we also study numerically three RBD mutations (E484K, N501Y and E484K/N501Y) found in the main SARS-CoV-2 variants of concerns.
Abstract: We find that corilagin could be as effective for RBD/E484K but less effective for the RBD/N501Y and RBD/E484K-N501Y mutants, while TGG strongly binds at relevant locations to all three mutants, demonstrating the significant interest of these molecules as potential inhibitors for variants of SARS-CoV-2.
Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants.
Abstract: Importantly, these two antibodies also showed efficient neutralizing activities to the variants including B.1.1.7 and B.1.351, and reacted with mutations of N501Y, E484K, and L452R, indicated that it may also neutralize the recent India endemic strain B.1.617.
Introduction: The recent emerging variants of concern observed in the United Kingdom (B.1.1.7 with mutations N501Y, A570D and del69/70), South Africa (B.1.351 with mutations K417N, E484K and N501Y), Brazil (P.1 and P.2 with mutations K417T, E484K and N501Y) (Long et al.) and India (B.1.617 with mutations L452R
Replicative Fitness of a SARS-CoV-2 20I/501Y.V1 Variant from Lineage B.1.1.7 in Human Reconstituted Bronchial Epithelium.
Introduction: This may be explained by the presence of the N501Y mutation in the receptor binding domain (RBD) of the spike protein, which enhances viral particle binding to the ACE2 receptor.
A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS-CoV-2 variants and wild-type of the virus.
Introduction: In particular, B.1.351 variant as a dominant variant in South Africa, characterized by three amino acid mutations on the K417N, E484K, and N501Y in RBD accompanying with four substitutions and a deletion in the N-terminal domain (NTD), decreased neutralization activity of antibodies induced by non-B.1.351 SARS-CoV-2 infection or vaccination and increased transmissibility.
Figure: (A-G) Sera with series of dilution inhibited infection of pseudovirus with or without mutation (WT, B.1.351, P.1, B.1.1.7, D614G, N501Y, E484K).
Figure: (C-F) Inhibition rate of RBD(WT), RBD(
Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants.
PMID: 34228597
2021
Human vaccines & immunotherapeutics
Abstract: Neutralization potency was retained for S variants including S477N, E484K, and N501Y, substitutions present in recent variants of concern.
Introduction: Substitutions N501Y (B.1.1.7) and E484K-N501Y (B.1.351) are present among variants of concern which also posses
Method: E484K-N501Y were escape mutants isolated from 2B04 using N501Y virus.
Method: N501Y and D614G were constructed using SARS-CoV-2 Wuhan-Hu-1 spike with substitution at N501 or D614 site, respectively, and rescued by using reverse genetic system.
Genomic monitoring unveil the early detection of the SARS-CoV-2 B.1.351 (beta) variant (20H/501Y.V2) in Brazil.
Result: P.1 defining mutations related to each genomic region were the following: ORF1ab: S1188L, K1795Q, E5665D; spike: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, H655Y, T1027I; Orf8: E92K; and nucleocapsid: P80.
Result: The B.1.351 VOC was characterized by K417N, E484K,
SARS_CoV_2 mutation literature information.
PMID: 
2021
Diagnostics (Basel, Switzerland)
Browser Board
Co-occurred Entities
Filtrator
ViMRT